Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose Escalated Radiation in Locally Advanced Pancreas Cancer (LAP100)
NCT06958328Phase 3Recruiting
- Sponsor
- NRG Oncology
- Start
- Aug 2025
- Primary completion
- Oct 2030
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial in pancreatic ductal adenocarcinoma (PDAC) (2 arms), sponsored by NRG Oncology. Primary endpoint: Overall Survival at 3 years. Started Aug 2025; status: recruiting.
02
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06958328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06958328.